'For quarter ending June 2024, standalone Net sales (including other operating income) of Pfizer has increased 5.93% to Rs 562.86 crore compared to quarter ended June 2023.
Operating profit margin has jumped from 20.84% to 31.53%, leading to 60.32% rise in operating profit to Rs 177.49 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 15.70% to 9.50%. Purchase of finished goods cost rose from 26.78% to 30.88%. Employee cost decreased from 17.05% to 15.04%. Other expenses fell from 20.28% to 15.36%.
Other income up 25.04% to Rs 41.84 crore. PBIDT rose 52.13% to Rs 219.33 crore. Provision for interest fell 26.48% to Rs 2.11 crore.
PBDT rose 53.73% to Rs 217.22 crore. Provision for depreciation down 6.11% to Rs 14.6 crore.
Profit before tax grew 61.13% to Rs 202.62 crore. Provision for tax was expense of Rs...
Pleaselogin & subscribe to view the full report.
More Reports
-
Revenue up 11% YoY to Rs 33562.9 crore in Q2FY2025
-
(18-Nov-2024)
Bharat Forge
-
-
|
|